Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018

NEXT STORY
INVENTIVA Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
PREV STORY
Global Flow Cytometry Market Will Reach USD 5,650.9 Million by 2023: Zion Market Research
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Athenex Pharmaceutical Division, an Athenex, Inc. Company, Launches Levothyroxine Sodium for Injection

BUFFALO, N.Y., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical ...

author_avatar
NASDAQ Market News

Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours

PRESS RELEASE Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid ...

author_avatar
NASDAQ Market News

Intuitive Surgical Reports New Employee Option Grants for December 2015

SUNNYVALE, Calif., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (Nasdaq:ISRG) today reported ...

author_avatar
NASDAQ Market News